ICD code Q81.0 – Epidermolysis bullosa simplex

Key takeaways

Q81.0 is the billable ICD-10-CM code for epidermolysis bullosa simplex (EBS), a congenital keratin-mutation disorder distinct from junctional (Q81.1) and dystrophic (Q81.2) epidermolysis bullosa.

All EBS subtypes (Koebner, Dowling-Meara, Weber-Cockayne) share Q81.0 because ICD-10-CM has no deeper codes, so the chart has to name the subtype for payers.

Q81.0 is exempt from present-on-admission (POA) reporting and valid in the current ICD-10-CM code set. Once confirmed, it carries forward as a chronic congenital diagnosis.

Pabau’s claims management software helps dermatology practices submit Q81.0 claims with the documentation payers require, which cuts denials on rare congenital diagnoses.

ICD-10 code Q81.0: Quick-reference code details

ICD-10 code Q81.0 is the valid, billable ICD-10-CM code for epidermolysis bullosa simplex in the current code set. It is a leaf-node code, so no further characters are needed. The table below summarizes the attributes to check before you submit a claim.

What does Q81.0 cover? The clinical scope of epidermolysis bullosa simplex

Q81.0 covers epidermolysis bullosa simplex (EBS), an inherited mechanobullous disorder in which blisters form within the epidermis rather than below the dermal-epidermal junction.

Mutations in KRT5 (keratin 5) or KRT14 (keratin 14) weaken the cytoskeleton of basal keratinocytes. Even minor friction or trauma then ruptures the cells and forms an intraepidermal blister.

According to WHO’s ICD-10 browser, Q81 encompasses all inherited forms of epidermolysis bullosa, with Q81.0 capturing the simplex variant specifically.

EBS is autosomal dominant in most cases, meaning a single inherited copy of the mutated allele is sufficient to cause disease. Onset is congenital or present within the first months of life.

The blistering is generally less severe than in junctional or dystrophic EB. The cleavage plane stays within the epidermis and spares the basement membrane zone.

EBS subtypes and their coding implications

Three clinically recognized EBS subtypes all map to Q81.0 because ICD-10-CM does not provide separate codes at a deeper level of specificity. Coders and clinicians often assume a more specific code exists, but the current edition has none.

Because all three subtypes share a single ICD-10-CM code, the subtype documentation in the clinical record carries disproportionate weight. Payers approving specialty biologics or gene therapies for Dowling-Meara, the most severe subtype, look for that detail in the chart note. The diagnosis code itself does not show it. Document the subtype by name whenever the clinical record establishes it.

Code hierarchy: Q81.0 within the Q81 category

Q81 is the parent category for all inherited forms of epidermolysis bullosa under the CDC/NCHS ICD-10-CM tabular list. Q81 is not billable on its own, so coders must assign a specific child code. The table below shows the full Q81 hierarchy and when to select each code.

Use Q81.0 only when the clinical record documents epidermolysis bullosa simplex specifically. If EB is confirmed but the type is not yet specified, use Q81.9 while genetic panel results are pending. Update to Q81.0 or the right sibling code once the subtype is confirmed.

The ICD-10-CM code guides in our library follow the same format for other diagnosis codes, from chapter placement to common denial triggers.

Excludes1 notes and coding restrictions for Q81.0

ICD-10-CM pairs the congenital Q81 codes with an Excludes1 note against acquired epidermolysis bullosa (L12.3). An Excludes1 note means the two conditions are mutually exclusive, so their codes never appear together on the same encounter claim.

• Excludes1 pairing: acquired epidermolysis bullosa, also called epidermolysis bullosa acquisita (EBA), is an autoimmune condition rather than a hereditary skin-fragility disorder. Its L12.3- codes cannot be reported with Q81.0 or any other Q81 code.
• Practical impact: if a chart mentions both congenital EBS and acquired epidermolysis bullosa, the claim cannot carry Q81.0 and an L12.3- code together. Code the condition the testing supports, and query the physician when the onset history or antibody results leave the type unclear.
• No Excludes2 notes exist at the Q81.0 level itself in the current ICD-10-CM edition. There are no “not included here, but may be coded additionally” restrictions beyond the Excludes1 pairing.

Codes commonly confused with Q81.0

Coding errors for epidermolysis bullosa simplex almost always fall into two patterns. Coders either pick an imprecise sibling code within the Q81 family, or select an acquired blistering code when the record supports a hereditary diagnosis.

Epidermolysis bullosa acquisita (L12.30) is the most frequent non-Q81 confusion. EBA is autoimmune and acquired in adulthood, so it is a different condition despite the shared name. A patient with adult-onset blistering driven by anti-collagen VII antibodies should never receive Q81.0.

The decision path below turns the onset history and the testing result into the right code.

Documentation requirements to support ICD-10 code Q81.0

Congenital codes carry a documentation burden that acquired-condition codes do not. The record must establish that the condition was present at or from birth, not simply that the patient has it now. For a Q81.0 claim, the chart must contain at minimum:

• Confirmatory diagnostic testing: electron microscopy showing intraepidermal cleavage at the basal keratinocytes, or immunofluorescence antigen mapping. Molecular genetic testing that identifies a KRT5 or KRT14 pathogenic variant also qualifies. Clinical suspicion alone does not support Q81.0.
• Physician attestation of congenital onset: a dated note confirming the condition was present at or from birth. A family history consistent with autosomal dominant inheritance also supports it.
• Subtype documentation: while no separate ICD-10-CM code exists for each EBS subtype, name the subtype (Koebner, Dowling-Meara, or Weber-Cockayne) in the assessment. Payers use this detail when reviewing prior authorization requests for high-cost treatments.
• Specialist involvement note: a dermatologist or geneticist referral note supporting the diagnosis strengthens the record for payer audits.

Once Q81.0 is established in the chart, it works as a permanent chronic diagnosis. Coders may carry it forward to later encounters without the treating clinician re-documenting the original workup each time. That holds as long as the note where the diagnosis was first established stays accessible.

That makes the initial diagnostic note the most important document to protect in the patient file.

Present-on-admission reporting for Q81.0

Q81.0 is exempt from present-on-admission (POA) reporting. As a congenital condition, epidermolysis bullosa simplex is present at birth and cannot be a hospital-acquired complication of care. Appendix I of the ICD-10-CM Official Guidelines tells inpatient coders to leave the POA field blank for exempt codes. Y, N, U, and W do not apply.

As a result, Q81.0 does not affect hospital-acquired condition (HAC) payment adjustments. Payers and auditors will not penalize a facility for a congenital blistering disorder, because the condition predates the encounter by definition. Reporting a Y or N indicator against Q81.0 on an inpatient claim is a coding error that may attract payer review.

Medicare and payer coverage for ICD-10 code Q81.0

Q81.0 alone does not guarantee reimbursement, because it must support a covered service. Medicare and commercial payers evaluate coverage at the procedure level. The diagnosis provides medical necessity.

Each CPT code billed alongside Q81.0 is then assessed against the relevant Local Coverage Determination (LCD) or National Coverage Determination (NCD).

Check the CMS ICD-10 codes page and your Medicare Administrative Contractor (MAC) LCD database before billing associated wound care, genetic testing, or biologic therapies.

Three coverage areas need specific attention for Q81.0 encounters. Ensuring medical billing compliance across all three protects the practice from retrospective audits.

• Wound care: debridement under CPT 97597 and its add-on 97598 is generally covered when Q81.0 supports chronic, non-healing wounds. Most MACs cover routine wound care under existing LCDs without prior authorization. Documentation of wound size, depth, and treatment response is still required.
• Genetic testing: molecular testing (KRT5/KRT14 panels in the CPT 81403-81405 range) requires specific LCD coverage. Some MACs cover targeted gene panels for rare hereditary skin disorders, while others require peer-to-peer review. Verify current MAC policy before ordering.
• Specialty biologics and gene therapies: emerging treatments for severe EBS subtypes carry orphan drug status. Prior authorization is almost always required. Q81.0 supports the diagnosis, but the request must also include the EBS subtype, severity documentation, and evidence that standard wound care was tried.

Common claim denial reasons for Q81.0

Rare congenital diagnosis codes attract more scrutiny than high-volume codes because payers have fewer reference claims to benchmark against. The denial patterns below account for most Q81.0 rejections, along with corrective actions for each.

• Missing confirmatory diagnostic testing: the claim passes the code validity check but the medical record contains no electron microscopy, immunofluorescence, or molecular genetic test result. Corrective action: obtain and attach the confirmatory test report before resubmission. Denial management workflows that flag missing attachments at the time of claim build prevent this from reaching the payer.
• Wrong Q81 subcode: Q81.9 (unspecified) submitted when the record already contains subtype documentation. Corrective action: re-read the clinical note, confirm the subtype, and resubmit with Q81.0 (or Q81.1/Q81.2 as appropriate). This correction does not require a physician query.
• Incorrect POA indicator: inpatient claim submitted with a Y or N indicator against Q81.0 instead of a blank field. Corrective action: resubmit with the POA field left blank. No clinical documentation change is needed.
• Procedure-diagnosis mismatch: a procedure is billed with Q81.0 as the only diagnosis, but its LCD requires more supporting codes. Debridement, for example, needs wound size and depth codes alongside it. Corrective action: add the appropriate anatomical or wound-characteristic codes.
• Missing prior authorization: specialty biologic or gene therapy billed without an auth number. Corrective action: obtain retroactive authorization where the payer allows it, or write off the claim and re-order with authorization in place.
• Non-covered investigational treatment: emerging EB therapies may not yet have an active coverage determination. Corrective action: issue an Advance Beneficiary Notice (ABN) before the service. Bill the patient directly when coverage is denied.

CPT codes commonly used alongside Q81.0

The CPT codes below represent the most frequent procedure pairings with ICD-10 code Q81.0 in dermatology and wound care settings. Confirm current CMS and MAC LCD coverage before billing. The AAPC’s ICD-10-CM lookup tool is a useful starting point for crosswalk verification.

For the diagnostic workup, a punch biopsy of a single lesion is billed as CPT 11104. A tangential sample, such as a shave, takes 11102 instead, and an incisional sample takes 11106.

How Pabau keeps Q81.0 claims complete before submission

Many Q81.0 denials trace back to a claim that left the practice without its supporting documents. The confirmatory test report sits in a lab portal, the subtype sits in a referral letter, and the payer sees neither.

Pabau, the practice management and billing platform we build, keeps the diagnosis, the visit note, and the claim in one patient record. With error-catching claims management connected to a US clearinghouse, pairing the right CPT code with Q81.0 and submitting a clean claim happen in one workflow.

Through Pabau’s Claim.MD clearinghouse integration, your front desk can also run eligibility checks before the encounter. You confirm coverage for Q81.0-associated procedures before the claim goes out, rather than after a denial comes back.

Reduce Q81.0 claim denials before they happen

Pabau’s claims management tools help dermatology practices submit rare congenital diagnosis claims with the documentation payers require. Run eligibility checks, attach supporting notes, and track claim status in one place.

Book a demo

Conclusion

Q81.0 rewards the practice that does its confirmation work once and does it well. Get the genetic, electron microscopy, or immunofluorescence result into the chart and name the subtype. From then on, the code can carry forward for the rest of the patient’s care.

The trade-off to remember is timing. Billing Q81.9 while the workup is pending is correct, but leaving it there after the subtype is confirmed invites avoidable denials. Build the switch to Q81.0 into the step where test results are filed.

To see how Pabau attaches that documentation before a rare congenital diagnosis claim leaves your practice, book a demo.

Continue your research

Looking for clearinghouse integration options? Medical claims clearinghouse explains how clearinghouses work, what they validate, and how to choose one for dermatology billing workflows.

Frequently asked questions